Recursion
SF 8.1AI biotech with cellular imaging and automation
AI biotech with cellular imaging and automation
AI-powered small molecule design
Quick decision guide
Overview
Recursion is an AI drug discovery company that uses cellular imaging, automation, and machine learning to identify and validate new drug candidates. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.
The clearest fit for Recursion is pharma collaborators and internal pipeline programs, with the platform leaning into phenomics platform with multimodal data. Limitations are real: direct buyer access is limited to partnerships. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should confirm validation depth, support coverage, and rollout plan before signing.
Atomwise is an AI-powered drug discovery platform that helps pharmaceutical and biotechnology organisations identify potential small-molecule medicines using deep learning. Built for research teams rather than individual users, it combines virtual screening, structure-based modelling and biological data analysis to support early-stage drug discovery.
• Built for pharmaceutical and biotechnology organisations seeking to accelerate small-molecule drug discovery with AI.
• Uses AtomNet deep learning technology to identify potential drug targets, screen compounds and support structure-based drug design.
• Supports drug discovery across multiple therapeutic areas through research partnerships with pharmaceutical companies.
• Available through partnership agreements rather than self-service, with custom pricing and implementation tailored to each organisation.
Atomwise is best suited to pharmaceutical and biotechnology organisations investing in AI-assisted drug discovery, although its partnership-based model may be less suitable for smaller research teams looking for self-service software.
Side-by-side
OVERLAP
Both tools cover similar catalog signals. The deciding factor is usually workflow fit, implementation needs, and ecosystem fit.
Shared capabilities
Shared workflows
Feature check
The trade-offs
Final verdict
Current catalog data shows meaningful overlap between Recursion and Atomwise. Use the signals below to decide based on workflow, ecosystem, pricing, and implementation fit.
Recursion and Atomwise share 8 catalog signals, so the decision should focus on fit rather than broad capability alone.
Recursion has 4 visible decision signals and Atomwise has 4.
Recursion has the higher SoftFinders Score in the current catalog data.